China (Mainland)
Diamondsupplier 
High quality Ciprofloxacin Hydrochloride CAS NO.86393-32-0
- Min.Order: 25 Kilogram
- Payment Terms: L/C,D/A,D/P,T/T,MoneyGram,Other
- Product Details
Keywords
- Ciprofloxacin Hydrochloride API powder
- CAS:86393-32-0
- Ciprofloxacin Hydrochloride
Quick Details
- ProName: High quality Ciprofloxacin Hydrochlori...
- CasNo: 86393-32-0
- Molecular Formula: C17H19ClFN3O3
- Appearance: light yellow crystaline powder
- Application: antibacterial agent
- DeliveryTime: within 7-10 days after order
- PackAge: 25kg/drum
- Port: Beijing/Shanghai/Hangzhou/Shenzhen
- ProductionCapacity: 10 Metric Ton/Month
- Purity: 98% up
- Storage: Keep in dry and room temperature
- Transportation: shipping by air, by sea or by courier ...
- LimitNum: 25 Kilogram
Superiority
1) Specialized in pharmaceutical industry since from 1987
2) ISO 9001:2015 & SGS audited supplier
3) Accept better payment terms : T.T 30-60 days.on the basic of pass SINOSURE credit investigation.
5) We have warehouse in USA with quickly shipment .
6) We can do different terms of FOB ,CIF/CIP ,DDP ...
Details
|
Product of Ciprofloxacin Hydrochloride |
|
Product name |
Ciprofloxacin hydrochloride |
|
|
Molecular Formula |
|
|
|
Molecular Weight |
|
|
|
CAS No. |
86483-48-9 |
|
|
Quality Standard |
USP43 |
|
|
Appearance |
light yellow crystaline powder |
|
COA of Ciprofloxacin Hydrochloride: |
|
Usage for Ciprofloxacin Hydrochloride: |
Ciprofloxacin hydrochloride, C17H18FN3O3 •HCl•H2O, is a synthetic broad-spectrum antibacterial agent. Ciprofloxacin differs from other quinolones in that it has a fluorine atom at the 6-position, a piperazine moiety at the 7-position, and a cyclopropyl ring at the 1-position. it was the drug of choice forcombating anthrax.
Ciprofloxacin hydrochloride (Cipro, 500-mg tablets) is highly active against the important bacterial causes of enteritis, including diarrheogenic Escherichia coli, Vibrio cholerae, Salmonella species, Shigella species, Campylobacter jejuni, Aeromonas species, and Yersinia enterocolitica.
